Skip to main content

Pharma News

pharma courses

 

gpat

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • Lilly Completes Acquisition of DICE Therapeutics

    Eli Lilly and Company announced the successful completion of its acquisition of DICE Therapeutics, Inc  The acquisition expands Lilly's immunology portfolio to include DICE's novel oral therapeutic candidates, including oral IL-17 inhibitors currently in clinical development, to treat chronic diseases in immunology.

  • Parliament passes the Anusandhan National Research Foundation (NRF) Bill, 2023

    Union Minister for Science & Technology Dr Jitendra Singh said here today that "Anusandhan National Research Foundation" will define the stature of India at 2047. Replying to the discussion on "Anusandhan National Research Foundation (NRF) Bill, 2023" in the Rajya Sabha, Dr Jitendra Singh said, the Anusandhan Act will pave the way for India to join the select league of developed nations.

  • Intas launches treatment of mild to moderate Atopic Dermatitis

    Intas launches of Topical TOFATAS – a DCGI-approved, Tofacitinib Ointment 2% w/w for the treatment of mild to moderate Atopic Dermatitis (AD) in patients 18 years and above having flare-ups of the disease.

  • Lupin Receives approval from USFDA for Turqoz

    Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

  • NIH launches long COVID clinical trials through RECOVER Initiative, opening enrollment

    The National Institutes of Health launched and is opening enrollment for phase 2 clinical trials that will evaluate at least four potential treatments for long COVID, with additional clinical trials to test at least seven more treatments expected in the coming months. Treatments will include drugs, biologics, medical devices and other therapies. The trials are designed to evaluate multiple treatments simultaneously to identify more swiftly those that are effective.

  • Merck breast cancer medicine meets trial endpoint

    Merck known as MSD outside of the United States and Canada, announced that the pivotal Phase 3 KEYNOTE-756 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemotherapy met one of its dual primary endpoints of pathological complete response (pCR) rate following the neoadjuvant part of the neoadjuvant/adjuvant study regimen in patients with high-risk, early-stage estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer.

  • Glenmark Pharma receives ANDA approval for Saxagliptin Tablets, 2.5 mg and 5 mg

    Glenmark Pharmaceuticals Ltd. is an integrated, research‐led, global pharmaceutical company, with a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology.

  • Gene Mutation May Explain why Some Don’t Get Sick from COVID-19

    People who contract COVID-19 but never develop symptoms the so-called super dodgers may have a genetic ace up their sleeve. They’re more than twice as likely as those who become symptomatic to carry a specific gene variation that helps them obliterate the virus, according to a new study led by UC San Francisco researchers. 

  • Machine Learning : Artificial Neural Networks Localize Extrasystoles

    Additional heartbeats from cardiac chambers, so-called ventricular extrasystoles, may be associated with severe diseases. Researchers at Karlsruhe Institute of Technology (KIT) use machine learning for their non-invasive localization. This may facilitate and improve future diagnosis and therapy. The researchers use artificial neural networks trained with synthetic data from a realistic simulation model. They report in Artificial Intelligence in Medicine.

  • FDA approves XDEMVY for the treatment of Demodex blepharitis

    Tarsus Pharmaceuticals, Inc, whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, announced that the U.S. Food and Drug Administration (FDA) approved XDEMVY (lotilaner ophthalmic solution) 0.25% for the treatment of Demodex blepharitis. XDEMVY, formerly known as TP-03, is the first and only FDA approved treatment to directly target Demodex mites, the root cause of Demodex blepharitis.

Subscribe to Pharma News